{"type":"PR","pr":{"number":197,"head":"92590cc520440d258b236c921232afc2d21f445e"},"user":"silvia.vernotico","status":"pending_publish","branch":"cms/2019-03-31-hot-this-week-in-farmaceutica-younger-n-94","collection":"hotthisweek","title":"HOT THIS WEEK IN FARMACEUTICA YOUNGER N.94","description":"La Food and drug administration statunitense ha dato il suo ok a Mayzent (siponimod), farmaco orale sviluppato da Novartis, per il trattamento di forme recidivanti di sclerosi multipla (SM) tra cui la sclerosi multipla secondaria progressiva (SPMS, secondary progressive MS) in forma attiva, la sclerosi multipla recidivante remittente (RRMS) e la sindrome clinicamente isolata (CIS).","objects":{"entry":{"path":"site/content/hotthisweek/2019-03-31-hot-this-week-in-farmaceutica-younger-n-94.md","sha":"246f2457c76633a1f04c69b5e81d30716d0bec62"},"files":[{"path":"/site/static/img/a804d48d-7834-462d-8282-1f932f64b715.jpeg","sha":"7ac2d42b66dbeeff2a220c99968a0a4c4abfb78a"}]},"timeStamp":"2019-03-31T07:56:59.897Z"}